# Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer

> **NCT00492258** · PHASE3 · COMPLETED · sponsor: **Medical Research Council** · enrollment: 1656 (estimated)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00492258
- **Lead sponsor:** Medical Research Council
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2012-08
- **Final completion:** 2012-12
- **Target enrollment:** 1656 (ESTIMATED)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492258, "Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00492258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*